Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease

Pediatrics
Melissa Berman-RosaCaroline Quach

Abstract

Pneumococcal conjugate vaccines (PCVs) (pneumococcal 13-valent conjugate vaccine [PCV-13] and pneumococcal 10-valent conjugate vaccine [PCV-10]) are available for prevention of pneumococcal infections in children. To determine the vaccine effectiveness (VE) of PCV-13 and PCV-10 in preventing invasive pneumococcal disease (IPD) and acute otitis media (AOM) in children <5 years. Systematic searches of Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, Web of Science, and Cochrane. Eligible studies examined the direct effectiveness and/or efficacy of PCV-10 and PCV-13 in reducing the incidence of disease in healthy children <5 years. Two reviewers independently conducted data extraction and methodologic quality assessment. Significant effectiveness against vaccine-type IPD in children ≤5 years was reported for ≥1 dose of PCV-13 in the 3 + 1 (86%-96%) and 2 + 1 schedule (67.2%-86%) and for PCV-10 for the 3 + 1 (72.8%-100%) and 2 + 1 schedules (92%-97%). In children <12 months of age, PCV-13 VE against serotype 19A post-primary series was significant for the 3 + 1 but not the 2 + 1 schedule. PCV-10 crossprotection against 19A was significant in children ≤5 years with ≥1 dose (82.2% and 71%). Neither PCVs were...Continue Reading

Citations

Aug 5, 2020·Human Vaccines & Immunotherapeutics·Erdem GönüllüMetin Karaböcüoğlu
Feb 11, 2021·Microorganisms·Bonggoo Park, George Y Liu
Jul 23, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shalom Ben-ShimolUNKNOWN Israeli Pediatric Bacteremia And Meningitis Group (Ipbmg), And The Israeli Adult Invasive Pneumococcal Disease (Iaipd) Group

❮ Previous
Next ❯

Related Concepts